STOCK TITAN

AXGN Form 144: Insider plans 14,937-share sale on 10/03/2025

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Axogen, Inc. insider filing shows a proposed sale of 14,937 common shares, with an aggregate market value of $267,073.56, through Morgan Stanley Smith Barney LLC on 10/03/2025. The shares were acquired as Restricted Stock Units on 09/01/2024. The filer declares no undisclosed material information and notes reliance on Rule 144 and any applicable 10b5-1 trading plan mechanics. The notice also reports recent sales on 10/02/2025 totaling 10,020 shares for gross proceeds of $180,424.04 executed under a 10b5-1 program and an irrevocable trust.

Positive

  • 14,937 shares identified for sale are explicitly from Restricted Stock Units acquired on 09/01/2024
  • Sale to be routed through a major broker: Morgan Stanley Smith Barney LLC, providing execution transparency
  • Filer attests to no undisclosed material information and references reliance on Rule 10b5-1 mechanics

Negative

  • Insider sold 7,620 and 2,400 shares on 10/02/2025 for combined gross proceeds of $180,424.04, indicating continued insider selling
  • Proposed sale of 14,937 shares represents incremental supply in the market on 10/03/2025

Insights

TL;DR: Insider proposes to sell 14,937 shares on 10/03/2025; prior sales of 10,020 shares occurred on 10/02/2025.

The filing discloses a planned sale of 14,937 common shares valued at $267,073.56 via Morgan Stanley Smith Barney LLC. These shares were granted as Restricted Stock Units on 09/01/2024, indicating the transaction relates to vested compensation rather than open-market purchases.

The schedule also records recent 10b5-1 sales and a trust sale totaling 10,020 shares for $180,424.04 on 10/02/2025, showing active disposition of shares over consecutive days. The filer affirms no undisclosed material information under the signature block.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What did Axogen (AXGN) report in this Form 144?

The filing reports a proposed sale of 14,937 common shares valued at $267,073.56, to be sold on 10/03/2025 through Morgan Stanley Smith Barney LLC.

When were the shares being sold by the filer acquired?

The shares were acquired as Restricted Stock Units on 09/01/2024.

Were there any recent insider sales disclosed?

Yes; the filing shows 10b5-1 sales on 10/02/2025 of 7,620 shares for $137,200.04 and a trust sale of 2,400 shares for $43,224.00.

Through which broker will the proposed sale be executed?

The sale is scheduled to be executed through Morgan Stanley Smith Barney LLC at 1 New York Plaza, 8th Floor, New York, NY 10004.

Does the filer claim any undisclosed material information?

No. By signing the notice, the person represents they do not know any material adverse information that has not been publicly disclosed.
Axogen Inc

NASDAQ:AXGN

AXGN Rankings

AXGN Latest News

AXGN Latest SEC Filings

AXGN Stock Data

1.51B
43.65M
4.79%
87.51%
5.58%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
ALACHUA